NeoGenomics's Total Assets for the quarter that ended in Mar. 2026 was MXN24,282 Mil.
During the past 12 months, NeoGenomics's average Total Assets Growth Rate was -3.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -2.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.60% per year.
During the past 13 years, NeoGenomics's highest 3-Year average Total Assets Growth Rate was 392.90%. The lowest was -2.70%. And the median was 38.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
NeoGenomics's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
NeoGenomics Total Assets Related Terms
NeoGenomics Total Assets Historical Data
* Premium members only.
The historical data trend for NeoGenomics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
NeoGenomics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (MEX:NEO) has a Total Assets of MXN24,282 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Total Assets too high?
NeoGenomics' current Total Assets is MXN24,282 Mil. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Assets compare to WGS and CDNA?
NeoGenomics' Total Assets of MXN24,282 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on NeoGenomics and its competitors. NeoGenomics's current Total Assets is MXN24,282 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (MEX:NEO) is currently considered Fairly Valued. The stock's GF Value™ is MXN193.14, compared to a current price of MXN176.40 — trading 8.7% below its estimated fair value. The current Total Assets is MXN24,282 Mil. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Total Assets is MXN24,282 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (MEX:NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued.
The current stock price of MXN176.40 is trading 8.7% below its estimated GF Value™ of MXN193.14.
GuruFocus considers NeoGenomics to be Fairly Valued.
Key valuation signals for MEX:NEO:
Total Assets: MXN24,282 Mil
GF Value™: MXN193.14 vs. price of MXN176.40 (8.7% below fair value)
No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score
Get the complete analysis for MEX:NEO
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NEO has been successfully added to your 
